Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych MEQs / SAQsConsultation-liaison psychiatry

Psych MEQs / SAQs · Consultation-liaison psychiatry

MS depression, suicide risk, PBA, and steroid mania (MEQ)

FRANZCP-style MEQ on MS depression, suicide, PBA, steroid mania, and joint neurology care.

20 marks20 min1 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 34-year-old woman with relapsing-remitting MS for 6 years is referred to CL after an optic neuritis relapse treated with high-dose intravenous methylprednisolone. Three days later she is sleepless, irritable, and grandiosely planning a business she cannot fund. Two months earlier her partner reported brief episodes of uncontrollable crying lasting seconds without feeling sad, which staff labelled 'depression.' She now discloses passive death wishes, PHQ-9 is high, and she asks to stop her interferon because 'it makes me suicidal.' Cognition is subjectively slow; she fears job loss. (i) Formulate the neuropsychiatric syndromes and key differentials. (ii) Outline acute management of the steroid-associated affective/psychotic risk state and suicide assessment. (iii) Plan definitive care for depression and PBA with psychological and pharmacological options including access issues for dextromethorphan/quinidine. (iv) Advise on DMT mood concerns, cognition, and shared disposition. (20 marks)

Model answer

Reveal model answerShowHide

(i) Formulation and differentials. Concurrent cluster: (a) steroid-associated manic/irritable affective state temporally linked to high-dose methylprednisolone; (b) likely major depression with passive suicidal ideation requiring full risk assessment (Goldman priority: MS depression is under-treated); (c) probable pseudobulbar affect (brief uncontrollable crying without sadness — not the same as depressive crying or bipolar lability); (d) subjective cognitive slowing with vocational threat.[1][8] Differentials: delirium/infection; primary bipolar disorder unmasked by steroids; interferon-related mood contribution versus multifactorial depression; pure demoralisation without MDD.[2][7]

(ii) Acute management. Joint neurology: review steroid course (stop further pulses/taper as medically appropriate), exclude infection/metabolic delirium, ensure sleep and safety, use short-term sedation/antipsychotic strategies if agitation or psychosis risk is high, capacity assessment. Explicit suicide assessment (ideation, plan, intent, means, supports) and crisis pathway if needed — MS does not lower the threshold for care.[2][6]

(iii) Depression and PBA. Depression: offer CBT, including telephone-delivered models for access; pharmacotherapy options include SSRIs with MS-relevant trial discussion of paroxetine (e.g. start 10 mg oral daily, titrate carefully with monitoring for sexual side effects, hyponatraemia, suicidality).[4][5] PBA: educate; where available dextromethorphan 20 mg/quinidine 10 mg oral per product schedule with QT/interaction checks; if unavailable, pragmatic SSRI discussion and neurology liaison.[3][8]

(iv) DMT, cognition, disposition. Do not stop interferon unilaterally for mood alone — multifactorial formulation and shared decision with neurology, acknowledging pharmacoepidemiologic context of antidepressant use across DMT classes.[7] Cognitive screening/neuropsychology if work threatened; MS clinic + mental health follow-up; safety plan; partner education about PBA versus mood. [2][6]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this meqs / saq. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References8ShowHide
  1. [1]Goldman Consensus Group The Goldman Consensus statement on depression in multiple sclerosis Mult Scler, 2005.PMID 15957516
  2. [2]Minden SL, Feinstein A, Kalb RC, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS Neurology, 2014.PMID 24376275
  3. [3]Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect Ann Neurol, 2010.PMID 20839238
  4. [4]Mohr DC, Hart SL, Julian L, et al. Telephone-administered psychotherapy for depression Arch Gen Psychiatry, 2005.PMID 16143732
  5. [5]Ehde DM, Kraft GH, Chwastiak L, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis Gen Hosp Psychiatry, 2008.PMID 18164939
  6. [6]Feinstein A, Pavisian B Multiple sclerosis and suicide Mult Scler, 2017.PMID 28327056
  7. [7]Patten SB, Williams JV, Metz LM Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis Mult Scler, 2008.PMID 17986504
  8. [8]Ghaffar O, Chamelian L, Feinstein A Neuroanatomy of pseudobulbar affect: a quantitative MRI study in multiple sclerosis J Neurol, 2008.PMID 18297331
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousMild cognitive impairment — diagnosis, conversion, and management (MEQ)Consultation-liaison psychiatryNextNormal pressure hydrocephalus and reversible dementias — MEQConsultation-liaison psychiatry